FDA Advisers Unanimously Endorse Bluebird’s Gene Therapy for Rare Disorder

Advisers to the FDA voted unanimously in favor of approving an investigational gene therapy from Bluebird Bio on Thursday, concluding that its benefits for children with a rare and deadly disorder outweigh a demonstrable risk of causing cancer.